Curis Names Andrew Uprichard COO.Business/Science Editors CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 30, 2000 Curis, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRIS) today announced the appointment of Andrew C. G. Uprichard as chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . Dr. Uprichard joins Curis from Pfizer Global Research and Development, where he was most recently vice president, drug development. He held a number of positions at the Parke-Davis division of Warner Lambert Company during an eleven-year period prior to its merger earlier this year with Pfizer, including senior director of the cardiovascular clinical group and senior director of the cardiovascular discovery effort. Dr. Uprichard was responsible for the complete range of compound development activities for the cardiovascular and anti-infective portfolios at Parke-Davis, from early pre-clinical development through commercialization. He helped set strategic priorities for drug development in these therapeutic areas and managed all related line functions, including chemical development, formulation, clinical pharmacology, clinical development, regulatory affairs, marketing, legal, supply chain and manufacturing. "Andrew Uprichard brings to Curis a dynamic and market-oriented approach to therapeutic product development," said Doros Platika, M.D., president and chief executive officer of Curis. "His extensive experience at a pharmaceutical industry leader encompasses virtually every important function required for successful drug development. Andrew is an outstanding addition to the Curis management team and arrives at a particularly opportune time." A medical graduate of the University of Edinburgh (body, education) University of Edinburgh - A university in the centre of Scotland's capital. The University of Edinburgh has been promoting and setting standards in education for over 400 years. , Scotland, Dr. Uprichard completed his residency training in the United Kingdom before taking positions as a cardiology fellow and postdoctoral research fellow at the University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries. Medical School. He is a fellow of the Royal College of Physicians The Royal College of Physicians of London was the first medical institution in England to receive a Royal Charter. It was founded in 1518 and is one of the most active of all medical professional organisations. in the United Kingdom and a fellow of the American College of Physicians The American College of Physicians (ACP) is a national organization of doctors of internal medicine (internists), physicians who specialize in the prevention, detection and treatment of illnesses in adults. . Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology Developmental biology A large field of investigation that includes the study of all changes associated with an organism as it progresses through the life cycle. The life cycles of all multicellular organisms exhibit many similarities. with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com. The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. The completion of a successful pre-clinical trial does not mean the Company will be able to successfully commercialize the product. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis joint proxy statement/prospectus filed with the Securities and Exchange Commission on June 19, 2000 and Quarterly Report on Form 10-Q Form 10-Q See 10-Q. filed with the Securities and Exchange Commission on November 14, 2000. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion